This grant from the National Institute on Drug Abuse aims to support research for the identification and development of safe and effective medications to treat Amphetamine and Amphetamine-like Related Disorders (ARDs), particularly focusing on methamphetamine abuse and dependence. With the prevalence of methamphetamine use being a major public health concern in the United States, this initiative seeks to address the lack of effective pharmacological treatments for ARDs. Researchers are encouraged to investigate preclinical and clinical approaches to combat the addictive properties and health effects of these substances.
Opportunity ID: 43905
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PA-07-334 |
| Funding Opportunity Title: | Medications Development for the Treatment of Amphetamine and Amphetamine-Like Related Disorders (R21) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.279 — Drug Abuse and Addiction Research Programs |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Dec 05, 2008 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – Multiple Receipt Dates – See Link to Full Announcement for details. |
| Current Closing Date for Applications: | – Multiple Receipt Dates – See Link to Full Announcement for details. |
| Archive Date: | Jun 07, 2010 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Independent school districts Small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) County governments |
| Additional Information on Eligibility: | Foreign institutions are eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Purpose. The goal of this program announcement is to encourage preclinical and clinical research directed towards the identification, evaluation and development of safe and effective medications for the treatment of Amphetamine and Amphetamine-like Related Disorders (ARDs), most importantly methamphetamine abuse and methamphetamine dependence. According to the DSM-IV-TR, the class of amphetamine and amphetamine-like substances includes all substances with a substituted-phenylethylamine structure, such as amphetamine, dextroamphetamine, methamphetamine, and MDMA (3,4-methylenedioxymethamphetamine). Also included are those substances that are structurally different but have amphetamine-like action, such as methylphenidate, some agents used as appetite suppressants, and khat. Amphetamines, amphetamine-like substances and methamphetamine especially, are highly addictive central nervous system stimulants that can be injected, snorted, smoked, or ingested orally. Of all the ARDs, prevalence data is most readily available for methamphetamine abuse and dependence. This data indicates that methamphetamine use continues to be a major public health concern in the United States for all segments of the population. Methamphetamine is unique in that it can be easily manufactured in clandestine laboratories using store-bought materials and is the most prevalent synthetic drug manufactured in the United States. The ease of manufacturing methamphetamine and its highly addictive potential has caused the use of the drug to greatly increase throughout the Nation. The methamphetamine problem was originally concentrated in the West of the United States, but has since spread throughout almost every major metropolitan area in the country, due to the low cost, high availability, and addictive properties of this substance. There are currently no effective pharmacological treatments for ARDs and there has been limited research focused on the identification and development of medications to treat these disorders, as well as research on the health effects of chronic abuse. For these reasons, the NIDA is encouraging research in this area. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PA-07-334.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.279 | ADOBE-FORMS-A | Adobe-Forms-A | PKG00009253 | Dec 05, 2008 | Feb 20, 2010 | View |
| 93.279 | ADOBE-FORMS-B | Use for submissions intended for due dates of January 25, 2010 and beyond | PKG00015184 | Dec 21, 2009 | May 07, 2010 | View |
Package 1
Mandatory forms
43905 RR_SF424-1.1.pdf
43905 RR_KeyPersonExpanded-1.1.pdf
43905 RR_OtherProjectInfo-1.1.pdf
43905 RR_PerformanceSite-1.1.pdf
43905 PHS398_CoverPageSupplement-1.1.pdf
43905 PHS398_ResearchPlan-1.1.pdf
43905 PHS398_Checklist-1.1.pdf
Optional forms
43905 PHS398_CoverLetter-1.1.pdf
43905 PHS398_ModularBudget-1.1.pdf
43905 RR_Budget-1.1.pdf
43905 RR_SubawardBudget-1.2.pdf
Package 2
Mandatory forms
43905 RR_SF424_1_2-1.2.pdf
43905 PerformanceSite_1_3-1.3.pdf
43905 RR_OtherProjectInfo_1_2-1.2.pdf
43905 RR_KeyPersonExpanded_1_2-1.2.pdf
43905 PHS398_CoverPageSupplement_1_4-1.4.pdf
43905 PHS398_ResearchPlan_1_3-1.3.pdf
43905 PHS398_Checklist_1_3-1.3.pdf
Optional forms
43905 PHS_CoverLetter_1_2-1.2.pdf
43905 PHS398_ModularBudget-1.1.pdf
43905 RR_Budget-1.1.pdf
43905 RR_SubawardBudget-1.2.pdf
Leave a Reply